TARDBP and amyotrophic lateral sclerosis: Approaches for modifying ALS mouse models to produce TDP-43 deposition are being explored, including injection of TDP-43 seeding aggregates into mice expressing human TDP-43 [54] to develop potential immunotherapy [55], or genetic strategies to mis-localize TDP-43 to the cytoplasm, for example, by mutating its nuclear localization signal [56, 57].